Survival Advantage with Cardiovascular Drugs: Are they Real?

Abstract

References

1. Singh BN . Antiarrhythmic drugs: A reorientation in light of recentdevelopments in the control of disorders of cardiac rhythm. Am J Cardiol 81:3D-13D, 1998

2. Singh BN . Significance and control of cardiac arrhythmias in patients with congestive heart failure. Heart Failure Revs 7:285-300, 2002

3. Singh BN . Rise and fall of guided antiarrhythmic therapy for ventricular tachycardiaand fibrillation. J Cardiovasc Pharmacol Therapeut 1:88-94, 1996

4. Packer M . Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog Cardiovasc Dis 41(Suppl 1)39-52, 1998

5. Packer M , Coats JC , Fowler P , et al. The Carvedilol Prospective Randomized Cumulative Survival Study Group. N Engl J Med 344:1651-1658, 2001

6. CIBIS II Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial. Lancet 353:9-13, 1999

7. MERIT-HF Study Group . Effect of metoprolol CRIXL in chronic heart failure (MERIT-HF). Lancet 353:2001-2007, 1999

8. Bristow MR . f-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000

9. Reiter MJ . Antiarrhythmic impact of anti-ischemic, antifailure and other cardiovascular strategies. Card Electrophysiolog Rev 4:194-205, 2000

10.

10. Vaughan CJ , Murphy MB , Buckley BM . Statins do more than just lower choleseterol. Lancet 348:1079-1082, 1996

11.

11. Libby P , Aikawa M . Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 8: 1257-1262, 2001

12.

12. Maron DJ , Fazio S , Linton MF . Current perspectives on statins. Circulation 101:207-213, 2000

13.

13. Miltiadous G , Mikhailidis DP , Elisaf MS . Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Therapeut 8:2003 (in press)

14.

14. Chiu TF , Bullard MJ , Chen JC , et al. Rapid life threatening hyperkalemia after addition of amiloride/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med 30:612-615, 1997

15.

15. Papadimitrio M , Vyzantiadis A , Milionis A , et al. The effect of spironolactone in hypertensive patients on regular hemodialysis and after renal allotransplantation. Life Support Systems 1:197-206, 1983

16.

16. Pitt B , Zannad F , Remme WJ , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 341:709-717, 1999